SVB Leerink Maintains Outperform on Zai Lab, Raises Price Target to $202
SVB Leerink analyst Jonathan Chang maintains Zai Lab (NASDAQ:ZLAB) with a Outperform and raises the price target from $192 to $202.
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.
Zai Lab Prices 5.5M ADS Public Offering @$47.50/ADS
Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB) announced the pricing of its underwritten public offering of…
98 Biotechnology Stocks Moving In Wednesday’s Session
Gainers • Neurotrope, Inc. (NASDAQ:NTRP) stock increased by 131.7% to $3.36 during Wednesday’s regular session. • Genprex, Inc.…
116 Healthcare Stocks Moving In Wednesday’s Session
Gainers • Neurotrope, Inc. (NASDAQ:NTRP) stock moved upwards by 133.1% to $3.38 during Wednesday’s regular session. • Genprex,…